课程预告丨基于小鼠模型的糖尿病及相关代谢疾病的机制研究和药效评价

Core Viewpoint - The article discusses the recent approval of MWN109, the world's first oral GLP-1/GIP/GCG receptor agonist, by the National Medical Products Administration (NMPA) for clinical trials, highlighting its significant weight loss effects and potential to lower blood sugar levels in diabetes patients [1]. Group 1: Global Diabetes Epidemiology and Disease Evolution - The global diabetes patient population has surpassed 800 million, with 140 million adult diabetes patients in China, showing a trend towards younger demographics [1]. Group 2: Limitations of Current Treatment Options - Despite the emergence of new drugs like GLP-1 receptor agonists and SGLT-2 inhibitors, diabetes treatment faces challenges such as high investment costs and low success rates in drug development, significant individual efficacy variability, and concerns regarding long-term safety [1]. Group 3: Cyagen's Metabolic Disease Efficacy Platform - Cyagen has established collaborations with various domestic and international pharmaceutical companies, biotechnology firms, and academic research institutions to create models for liver disease, obesity, diabetes, hyperuricemia, and atherosclerosis, aiding in disease research and new drug development [12][20]. Group 4: Online Classroom Announcement - Cyagen will host an online class titled "Empowering Diabetes Drug Development: Preclinical Efficacy Evaluation Based on Metabolic Disease Platform" on May 22, featuring Dr. Wu Zongmei, who will share insights on the global diabetes landscape and drug development dynamics, as well as key technical challenges in constructing preclinical models for diabetes [1].